Aventis Apidra Clears FDA; Rapid-Acting Insulin Launch Awaits Delivery Device Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis will wait until the OptiClick delivery device is approved before launching Apidra; the company filed for approval of the device in February. The rapid-acting insulin is approved by FDA April 16.